Skip Ribbon Commands
Skip to main content
Dr Tai Wai Meng David from National Cancer Centre Singapore

Dr Tai Wai Meng David

MBBS (NUS), MRCP, Royal College of Physicians, Specialist Accreditation for Medical Oncology, Academy of Medicine, Singapore 

Senior Consultant

Specialty: Medical Oncology

Sub-specialties: Hepato-Pancreato-Biliary, Colorectal, Upper Gastrointestinal

Conditions Treated by this Doctor:
Colorectal Cancer, Hepato-Pancreato-Biliary Cancers, Upper Gastrointestinal Cancers.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Adjunct Assistant Professor
  • Clinical Lecturer


Dr David Tai is a Senior Consultant Medical Oncologist at National Cancer Centre Singapore. His area of interest is in gastrointestinal cancers and early developmental therapeutics. The research focus involves integrating basic science and translational models in devising new therapy for gastrointestinal malignancies. He is also involved in multiple ongoing trials focusing mainly on gastrointestinal cancers and phase 1 efforts.


  • MRCP, Royal College of Physicians 
  • MBBS, National University of Singapore

Professional Appointments and Committee Memberships

  • Treasurer, Singapore Society of Oncology 
  • Member, Fellow of Academy of Medicine Singapore 


  • Outstanding Faculty Award Singhealth Residency 2016 
  • Health Manpower Development Programme Award 2013 
  • Singapore Health Quality Service Award 2010 – Silver Award 
  • SingHealth Best Registrar 2010 and 2011 
  • SingHealth Best Medical Officer 2007

Research Interests

  • Translational Research in Gastrointestinal Malignancies with special interests in hepato-pancretico-biliary cancers. 
  • Early Phase Developmental Therapeutics – merging preclinical evidence to rationale design of Phase I trials. 

Publications and Research Trials

  • Tan HL, Chia CS, Tan GH, Choo SP, Tai DW, Chua CW, Ng MC, Soo KC, Teo MC. Gastric peritoneal carcinomatosis - a retrospective review. World J Gastrointest Oncol. 2017 Mar 15;9(3):121-128. 
  • Teo R, Goh BK, Tai DW, Allen JC, Lim TK, Hwang JS, Tan DM, Lee SY, Chan CY, Cheow PC, Chow PK, Ooi LL, Chung AY, Ong S. Validation and comparison between current prognostication systems for pancreatic neuroendocrine neoplasms: A single-institution experience with 176 patients. Surgery. 2017 Jan 19. pii: S0039-6060(16)30852-2. 
  • Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2016 Dec;27(12):2210-2215 
  • Goh BK, Teo JY, Allen JC Jr, Tan DM, Chan CY, Lee SY, Tai DW, Thng CH, Cheow PC, Chow PK, Ooi LL, Chung AY. Preoperative platelet-to-lymphocyte ratio improves the performance of the international consensus guidelines in predicting malignant pancreatic cystic neoplasms. Pancreatology. 2016 Jun 26. pii: S1424-3903(16)31135-8. doi: 10. 
  • Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016 Apr;5(2):97-106. doi: 10.1159/000367759. Epub 2016 Mar 17. 
  • Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol. 2016 Mar 23. [Epub ahead of print] 
  • Tay GC, Iyer NG, Ong WS, Tai D, Ang MK, Ha TC, Soo KC, Tan HK. Outcomes and Prognostic Factors of Radiation-Induced and De Novo Head and Neck Squamous Cell Carcinomas. Otolaryngol Head Neck Surg. 2016 Mar 8. [Epub ahead of print] 
  • Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2016 Jan 1;138(1):195-205. 
  • Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, Lieu CH. Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist. 2015 Oct;20(10):1189-98. Goh BK, Tan DM, Chan CY, Lee SY, Lee VT, Thng CH, Low AS, Tai DW, Cheow PC, Chow PK, Ooi LL, Chung AY. Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms? J Surg Oncol. 2015 Sep;112(4):366-71.

Research Trials

  • Circulating Tumour DNA as a Biomarker Pancreatic Cancer 
  • A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma 
  • A Phase 1/2 Study of BMS-986183 in Subjects with Advanced Hepatocellular Carcinoma. 
  • A Phase 2A, single arm, multi-centre,study of ASLAN 001 in patients with advanced or metastatic cholangiocarcinoma who progressed on at least 1 line of systemic therapy. 
  • Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib) 
  • A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma